Dermatofibrosarcoma Protuberans (DFSP)

COL1A1-PDGFB fusion–driven dermal sarcoma with locally aggressive but rarely metastatic behavior — wide local excision and imatinib as molecularly targeted therapy for unresectable disease

Key Points

• DFSP is a rare, locally aggressive dermal sarcoma arising from dermal fibroblasts, accounting for ~0.1% of all malignancies and ~2–6% of all soft tissue sarcomas; it occurs most commonly on the trunk and proximal extremities of young to middle-aged adults.
• The hallmark molecular event is a chromosomal translocation t(17;22)(q22;q13) — present in >90% of DFSPs — fusing the COL1A1 (collagen type 1 alpha 1) gene to PDGFB (platelet-derived growth factor B), placing PDGFB under the constitutively active COL1A1 promoter and driving autocrine PDGFR-β signaling.
• DFSP has a characteristically infiltrative growth pattern extending well beyond its clinically apparent margins through finger-like projections along fascial planes, making surgical margin assessment critical; standard excision has local recurrence rates of 20–50%, whereas Mohs micrographic surgery (MMS) or wide local excision with 2–3 cm margins and peripheral/deep margin mapping achieves local recurrence rates <5%.
• Imatinib is FDA-approved for unresectable, recurrent, or metastatic DFSP; it inhibits the COL1A1-PDGFB–driven PDGFR-β signaling and achieves overall response rates of ~45–70% in COL1A1-PDGFB–positive tumors; PDGFB rearrangement testing is recommended before use.
• Fibrosarcomatous transformation (FS-DFSP) occurs in ~10–15% of DFSPs — the fibrosarcomatous areas acquire high-grade spindle cell morphology, increased mitotic rate, and significantly higher metastatic risk (~10–15% vs. <5% for classic DFSP); FS-DFSP is managed as high-grade sarcoma and may require adjuvant chemotherapy.
• Distant metastases in classic DFSP are rare (<5%); when they occur, they most commonly involve the lung; the COL1A1-PDGFB fusion is retained in metastatic lesions, maintaining imatinib sensitivity.

Epidemiology, Pathogenesis, and Molecular Biology

DFSP is diagnosed in approximately 4–5 cases per million persons per year in the United States — approximately 1,000 new cases annually. It affects all races but has a slightly higher incidence in Black individuals. Peak incidence is in the third to fifth decades; it is rare in children (though congenital DFSP does occur). There is no strong sex predilection. The trunk (40–50%), proximal extremities (30–40%), and head/neck (10–15%) are the most common anatomic sites. **Pathogenesis — COL1A1-PDGFB Fusion:** The defining molecular event in DFSP is a chromosomal translocation — most commonly…

Clinical Presentation and Diagnosis

**Clinical Presentation:** DFSP classically presents as a slow-growing, indurated plaque or nodule on the trunk or proximal extremity. The clinical evolution is characteristic — an initial indolent plaque phase lasting months to years, followed by the emergence of one or more nodular protuberances (hence the name "protuberans") signaling accelerated growth. The overlying skin may appear violaceous, erythematous, or skin-colored; telangiectasias are sometimes visible. Ulceration is uncommon in classic DFSP but occurs with fibrosarcomatous transformation or neglected disease. The lesion is…

Staging and Risk Stratification

DFSP is staged using the AJCC soft tissue sarcoma TNM system (8th edition), though its clinical behavior (locally aggressive, rarely metastatic) differs substantially from other soft tissue sarcomas. **T classification:** - T1: ≤5 cm - T2: 5–10 cm - T3: 10–15 cm - T4: >15 cm **Grade:** Classic DFSP is classified as low-grade (G1); fibrosarcomatous DFSP is high-grade (G2–3). Grade is the most important determinant of metastatic risk: - Classic DFSP (G1): Metastatic risk <2–5% overall - FS-DFSP (G2–3): Metastatic risk ~10–15%; lymph node involvement possible **Prognostic factors for local…

Treatment — Surgery

Surgery is the definitive treatment for localized DFSP. The critical principle is achieving clear margins — the infiltrative, finger-like subcutaneous extensions of DFSP extend an average of 2–3 cm beyond the clinically and radiographically apparent tumor edge, making clinical margin assessment unreliable. **Mohs Micrographic Surgery (MMS) — preferred for anatomically challenging sites:** MMS provides real-time complete peripheral and deep margin mapping using horizontal frozen sections that examine 100% of the surgical margin. Serial tangential excisions are performed until all margins are…

Treatment — Imatinib and Systemic Therapy

**Imatinib (FDA-approved for unresectable, recurrent, or metastatic DFSP):** Imatinib 400–800 mg/day is the standard systemic therapy for DFSP not amenable to surgical resection. The COL1A1-PDGFB fusion drives PDGFR-β signaling — the direct target of imatinib — providing a strong mechanistic rationale. Clinical evidence: - Multiple phase II trials and case series have demonstrated ORR ~45–70% in COL1A1-PDGFB–positive DFSP - The EORTC 62027 phase II trial demonstrated ORR 46% with imatinib 400 mg/day in unresectable/metastatic DFSP; responses were durable in most responders - Responses allow…

Surveillance and Prognosis

**Surveillance:** Given the high local recurrence rate of DFSP (especially with suboptimal margins) and the long natural history, long-term follow-up is essential: - Physical examination of the surgical site every 3–6 months for the first 3 years, then every 6–12 months for years 4–10, then annually - MRI of the primary site: Annually for 3–5 years, or if new symptoms develop; MRI is superior to clinical examination for detecting subclinical local recurrence in deep or post-reconstructed sites - CT chest: Every 6–12 months for 2–3 years for FS-DFSP; not routinely required for classic DFSP…